Want to see BCRX full AI Analyst Report?
BioCryst (BCRX) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Avoralstat | Diabetic Macular Edema (Dme) | Phase I | Recruiting | A Study of Avoralstat In Participants With Diabetic Macular Edema | Sep 26, 2025 | ― |
| Bcx17725 | Netherton Syndrome | Phase I | Recruiting | A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725 | Jul 30, 2024 | ― |
| Bcx10013 | Paroxysmal Nocturnal Hemoglobinuria | Phase I | Completed | Dose Escalation of BCX10013 in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH) | Oct 20, 2023 | ― |
| Bcx9930 | Paroxysmal Nocturnal Hemoglobinuria | Phase II | Terminated | Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria | Feb 14, 2023 | ― |
| Berotralstat | Hereditary Angioedema, Pediatric | Phase III | Active Not Recruiting | Berotralstat Treatment in Children With Hereditary Angioedema | Jun 30, 2022 | ― |
| Bcx9930 | Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, Membranous Nephropathy | Phase II | Terminated | Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN) | Nov 26, 2021 | ― |
| Bcx9930 Monotherapy | Paroxysmal Nocturnal Hemoglobinuria (Pnh) | Phase II | Terminated | BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Complement Inhibitor Therapy | Nov 02, 2021 | ― |
| Ravulizumab, Eculizumab, Bcx9930 | Paroxysmal Nocturnal Hemoglobinuria (Pnh) | Phase II | Terminated | BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy | Nov 02, 2021 | ― |
| Berotralstat | Hae, Hereditary Angioedema | Phase III | Active Not Recruiting | Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies | Jun 14, 2021 | ― |
| Ravulizumab, Eculizumab, Bcx9930 | Paroxysmal Nocturnal Hemoglobinuria, Pnh | Phase II | Terminated | A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | Jan 07, 2021 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Avoralstat | Phase I | Diabetic Macular Edema (Dme) | Recruiting | A Study of Avoralstat In Participants With Diabetic Macular Edema | Sep 26, 2025 | ― |
| Bcx17725 | Phase I | Netherton Syndrome | Recruiting | A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725 | Jul 30, 2024 | ― |
| Bcx10013 | Phase I | Paroxysmal Nocturnal Hemoglobinuria | Completed | Dose Escalation of BCX10013 in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH) | Oct 20, 2023 | ― |
| Bcx9930 | Phase II | Paroxysmal Nocturnal Hemoglobinuria | Terminated | Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria | Feb 14, 2023 | ― |
| Berotralstat | Phase III | Hereditary Angioedema, Pediatric | Active Not Recruiting | Berotralstat Treatment in Children With Hereditary Angioedema | Jun 30, 2022 | ― |
| Bcx9930 | Phase II | Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, Membranous Nephropathy | Terminated | Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN) | Nov 26, 2021 | ― |
| Bcx9930 Monotherapy | Phase II | Paroxysmal Nocturnal Hemoglobinuria (Pnh) | Terminated | BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Complement Inhibitor Therapy | Nov 02, 2021 | ― |
| Ravulizumab, Eculizumab, Bcx9930 | Phase II | Paroxysmal Nocturnal Hemoglobinuria (Pnh) | Terminated | BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy | Nov 02, 2021 | ― |
| Berotralstat | Phase III | Hae, Hereditary Angioedema | Active Not Recruiting | Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies | Jun 14, 2021 | ― |
| Ravulizumab, Eculizumab, Bcx9930 | Phase II | Paroxysmal Nocturnal Hemoglobinuria, Pnh | Terminated | A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | Jan 07, 2021 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does BioCryst Pharmaceuticals (BCRX) have in its pipeline
BioCryst BCRX is currently developing the following drugs: Avoralstat, Bcx17725, Bcx10013, Bcx9930, Berotralstat, Bcx9930 Monotherapy, Ravulizumab, Eculizumab, Bcx9930, Galidesivir, Bcx7353 Capsules, Bcx7353, Rosuvastatin, Bcx7353, Digoxin, Bcx7353 + Digoxin, Rosuvastatin + Bcx7353, Cyclosporine + Bcx7353, Bcx7353 And Probes, Peramivir, Oseltamivir, Peramivir, Bcx4430, Bcx4161. These drug candidates are in various stages of clinical development as the company works toward FDA approval.